Stockley’s Drug Interactions is the most indispensable source of drug interaction information available.
It provides expertly authored advice on managing drug interactions, and will quickly and reliably help you decide your best course of action.
SubscribeContent Updates
With over 4,500 detailed records, access drug-drug, drug-herb, drug-food interactions and much more
Featuring a concise summary at the start of each record, you can also discover the clinical evidence, mechanism, importance and management of each interaction
Contains detailed, fully referenced and international information with an unrivalled depth of content
*based on average data in the last 12 months
Stockley’s Drug Interactions update with new and revised monographs.
This update contains 3 new monographs and 12 revised monographs. The monographs on tetrabenazine have been fully revised and updated, and the related drugs, deutetrabenazine and valbenazine have been added.
Stockley’s Drug Interactions update with new and revised monographs.
This update contains 13 new monographs and 24 revised monographs. The monographs on the growth hormone release stimulants have been revised, with the addition of macimorelin, somatorelin, and tesamorelin. The sections on sevelamer and sodium oxybate have been re-validated and updated, and verteporfin has been added.
Stockley’s Drug Interactions update with new and revised monographs.
For this update, the monographs on the anti-androgens have been completely re-validated and updated, and apalutamide has been added. There are 7 new monographs and 31 existing monographs have been updated.
Stockley’s Drug Interactions update with new and revised monographs.
This update contains 2 new monographs, and 57 existing monographs have been updated. The chapter on the calcium channel blockers has been completely re-validated and updated.
Stockley’s Drug Interactions update with new and revised monographs.
For this update, several sections have been completely re-validated and updated, including those on abiraterone, the cannabinoids, and methotrexate. New drugs that have been added include lorcaserin, pimavanserin, pitolisant, telotristat ethyl, and tezacaftor. This update contains 42 new monographs, and 149 existing monographs have been updated.
Stockley’s Drug Interactions update with new and revised monographs.
For this update, new classification tables of inhibitors and substrates of the drug transporter proteins BCRP, MATE, OAT, OATP, and OCT, based on clinical pharmacokinetic data have been added, along with a new table of drugs that lower the seizure threshold. Several sections have been completely re-validated and updated, including those on HCV drugs and the HIV-protease inhibitors. This update contains 39 new monographs, and 692 existing monographs have been updated.
